GSK (NYSE:GSK) Rating Lowered to Underweight at Barclays

GSK (NYSE:GSK) was downgraded by stock analysts at Barclays from an “equal weight” rating to an “underweight” rating in a note issued to investors on Tuesday.

Several other research firms have also recently weighed in on GSK. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research note on Monday, October 27th. HSBC reaffirmed a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Bank of America upgraded shares of GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a report on Monday, December 29th. Finally, Cfra set a $53.00 price objective on shares of GSK in a research note on Thursday, October 30th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $44.13.

GSK Price Performance

Shares of NYSE:GSK traded up $1.51 during trading on Tuesday, reaching $50.53. 2,905,141 shares of the company traded hands, compared to its average volume of 3,795,319. The firm has a market capitalization of $103.00 billion, a PE ratio of 14.25, a PEG ratio of 1.25 and a beta of 0.45. The company’s 50 day moving average is $47.91 and its two-hundred day moving average is $42.79. GSK has a 52 week low of $31.72 and a 52 week high of $51.46. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to the consensus estimate of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 48.64%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, sell-side analysts predict that GSK will post 4.14 earnings per share for the current year.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 1,470,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider directly owned 18,245,691 shares of the company’s stock, valued at $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On GSK

Hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Peaks Wealth Advisors LLC bought a new position in shares of GSK in the 2nd quarter worth about $25,000. CNB Bank bought a new position in shares of GSK during the 3rd quarter worth approximately $31,000. SOA Wealth Advisors LLC. grew its position in shares of GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 605 shares during the period. CoreFirst Bank & Trust bought a new stake in shares of GSK in the 2nd quarter valued at $33,000. Finally, MTM Investment Management LLC acquired a new position in shares of GSK during the 2nd quarter valued at $37,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.